Loading...
Market
How will Vertex Pharmaceuticals' stock price change within 1 week following the resolution of the Casgevy gene therapy fertility support program lawsuit?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock market data from reputable financial sources such as Bloomberg or Reuters
Story
Vertex Pharmaceuticals Sues US Government Over Casgevy Gene Therapy Fertility Support Program
Jul 15, 2024, 06:12 PM
On July 15, Vertex Pharmaceuticals filed a lawsuit against the US government, specifically the US Department of Health and Human Services, seeking a court declaration that a fertility support program for patients prescribed its gene editing therapy, Casgevy, does not violate federal anti-kickback laws. The company is requesting permission to pay for fertility treatment for individuals who receive the Casgevy gene therapy, which can interfere with reproduction.
View original story
Similar markets
Yes • 50%
No • 50%
Vertex allowed to pay for fertility treatment • 25%
Vertex not allowed to pay for fertility treatment • 25%
Settlement with conditions • 25%
Case unresolved • 25%
Vertex wins • 25%
HHS wins • 25%
Settlement reached • 25%
Case dismissed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Does not violate • 25%
Violates • 25%
Partially violates • 25%
No ruling • 25%
Increase by more than 10% • 25%
Increase by 0% to 10% • 25%
No significant change • 25%
Decrease • 25%
Increase by over 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by over 5% • 25%
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change • 25%
Increase or decrease by less than 10% • 25%